

Blodcancerregistret

Akut lymfatisk leukemi (ALL)

1. Kozlowski P, Lennmyr E, Ahlberg L, Bernell P, Hulegårdh E, Karbach H, et al. **Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden.** European journal of haematology. 2017;99(2):141-9.
2. Bergfelt E KP, Ahlberg L, Bernell P, Hulegårdh E, Karbach H, Karlsson K, Tomaszewska-Toporska B, Åström M, Hallböök H. **Relapse of acute lymphoblastic leukaemia in older/elderly patients – a Swedish population-based study** European Haematology Association 2016.
3. Bergfelt E, Kozlowski P, Ahlberg L, Hulegårdh E, Hägglund H, Karlsson K, et al. **Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.** Medical oncology (Northwood, London, England). 2015;32(4):135.
4. Hulegårdh E, Hägglund H, Ahlberg L, Karlsson K, Karbach H, Markuszewska A, et al. **Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.** Medical oncology (Northwood, London, England). 2014;31(8):66.
5. Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, et al. **High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.** European journal of haematology. 2014;92(5):377-81.
6. Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, et al. **High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.** Haematologica. 2012;97(9):1414-21.
7. Juliusson G, Karlsson K, Hallböök H. **Population-based analyses in adult acute lymphoblastic leukemia.** Blood. 2010;116(6):1011; author reply 2.

Akut myeloisk leukemi (AML)

1. Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf A, Garelius H, et al. **Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.** Leukemia. 2017;31(3):728-31.
2. Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf A, Garelius H, Lazarevic V, et al. **Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.** Leukemia. 2017;31(6):1457-9.
3. Lazarevic VL, Rosso A, Juliusson G, Antunovic P, Derolf AR, Deneberg S, et al. **Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.** European journal of haematology. 2017;98(5):493-500.
4. Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, et al. **Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.** Blood. 2017;130(15):1713-21.
5. Juliusson G, Hough R. **Leukemia.** Progress in tumor research. 2016;43:87-100.
6. Wennström L, Edslev PW, Abrahamsson J, Norgaard JM, Floisand Y, Forestier E, et al. **Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries.** Pediatric blood & cancer. 2016;63(1):83-92.

7. Lazarevic V, Rosso A, Juliusson G, Antunovic P, Rangert-Derolf A, Lehmann S, et al. **Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.** American journal of hematology. 2015;90(9):800-5.
8. Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A, et al. **Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.** American journal of hematology. 2015;90(3):208-14.
9. Lazarevic V, Horstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, et al. **Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.** European journal of haematology. 2015;94(5):419-23.
10. Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, et al. **Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.** Blood cancer journal. 2014;4:e188.
11. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Höglund M. **Acute myeloid leukemia in the real world: why population-based registries are needed.** Blood. 2012;119(17):3890-9.
12. Juliusson G, Karlsson K, Lazarevic V, Wahlin A, Brune M, Antunovic P, et al. **Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.** Cancer. 2011;117(18):4238-46.
13. Juliusson G. **Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment.** Blood. 2011;117(12):3473-4.
14. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. **Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.** Leukemia. 2011;25(7):1128-34.
15. Juliusson G. **Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry.** Clinical lymphoma, myeloma & leukemia. 2011;11 Suppl 1:S54-9.
16. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. **Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.** Blood. 2009;113(18):4179-87.
17. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglunds M, Karlsson K, et al. **Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.** Leukemia. 2006;20(1):42-7.

Kronisk lymfatisk leukemi (KLL)

1. **Kronisk Lymfatisk Leukemi. Nationellt kvalitetsregister. Årsrapport nr 2, 2007-2014**
Stockholm: Regionalt cancercentrum i Samverkan; 2016. Available from:
<https://www.cancercentrum.se/samverkan/cancerdiagnoser/blod-lymfom-myelom/kronisk-lymfatisk-leukemi-kll/kvalitetsregister/>.

Kronisk myeloisk leukemi (KML)

1. Soderlund S, Dahlén T, Sandin F, Olsson-Strömberg U, Creignou M, Dreimane A, et al. **Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register.** European journal of haematology. 2017;98(1):57-66.
2. Lärfors G, Sandin F, Richter J, Sjalander A, Stenke L, Lambe M, et al. **The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.** European journal of haematology. 2017;98(4):398-406.
3. Gunnarsson N, Höglund M, Stenke L, Sandin F, Björkholm M, Dreimane A, et al. **No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden.** Leukemia. 2017;31(8):1825-7.
4. Gunnarsson N, Sandin F, Höglund M, Stenke L, Björkholm M, Lambe M, et al. **Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.** European journal of haematology. 2016;97(4):387-92.
5. Gunnarsson N, Höglund M, Stenke L, Wallberg-Jonsson S, Sandin F, Björkholm M, et al. **Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.** Leukemia. 2016;30(7):1562-7.
6. Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, et al. **Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.** Annals of internal medicine. 2016;165(3):161-6.
7. Gunnarsson N, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, et al. **Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.** British journal of haematology. 2015;169(5):683-8.
8. Höglund M, Sandin F, Simonsson B. **Epidemiology of chronic myeloid leukaemia: an update.** Annals of hematology. 2015;94 Suppl 2:S241-7.
9. Höglund M, Sandin F, Hellström K, Bjoreman M, Björkholm M, Brune M, et al. **Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.** Blood. 2013;122(7):1284-92.

Lymfom

Burkitt lymfom

1. Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D'Amore F, et al. **Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.** Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24(7):1879-86.
2. Wästerlid T, Jonsson B, Hagberg H, Jerkeman M. **Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.** Leukemia & lymphoma. 2011;52(11):2090-6.

CNS-lymfom

1. Eloranta S, Branvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G, et al. **Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013.** European journal of haematology. 2018;100(1):61-8.

Diffust storcelligt B-cellslymfom

1. Bicler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Smedby KE, et al. **Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI.** Cancer medicine. 2018;7(1):114-22.
2. Wästerlid T, Hartman L, Szekely E, Jerkeman M. **Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.** Hematological oncology. 2017;35(2):151-7.
3. Melen CM, Enblad G, Sonnevi K, Junlén HR, Smedby KE, Jerkeman M, et al. **Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.** British journal of haematology. 2016;175(4):614-22.
4. Szekely E, Linden O, Peterson S, Jerkeman M. **Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.** European journal of haematology. 2016;97(4):393-8.
5. El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Szekely E, et al. **Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.** Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(34):3993-8.
6. Hedström G, Peterson S, Berglund M, Jerkeman M, Enblad G. **Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study.** Acta oncologica (Stockholm, Sweden). 2015;54(6):924-32.
7. Hedström G, Hagberg O, Jerkeman M, Enblad G. **The impact of age on survival of diffuse large B-cell lymphoma - a population-based study.** Acta oncologica (Stockholm, Sweden). 2015;54(6):916-23.
8. Szekely E, Hagberg O, Arnljots K, Jerkeman M. **Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study.** Leukemia & lymphoma. 2014;55(8):1838-43.

Follikulärt lymfom

1. Junlén HR, Peterson S, Kimby E, Lockmer S, Linden O, Nilsson-Ehle H, et al. **Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.** Leukemia. 2015;29(3):668-76.

Hodgkins lymfom

1. Molin D, Linderöth J, Wahlin BE. **Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.** British journal of haematology. 2017;177(3):449-56.
2. Cheah CY, Brockelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, et al. **Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.** American journal of hematology. 2016;91(9):894-9.
3. Jakobsen LH, Hutchings M, de Nully Brown P, Linderöth J, Mylam KJ, Molin D, et al. **No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.** British journal of haematology. 2016;173(2):236-44.
4. Weibull CE, Eloranta S, Smedby KE, Björkholm M, Kristinsson SY, Johansson AL, et al. **Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.** Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(4):337-44.
5. Glimelius I, Ekberg S, Jerkeman M, Chang ET, Björkholm M, Andersson TM, et al. **Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics.** American journal of hematology. 2015;90(12):1128-34.
6. Glimelius I, Ekberg S, Linderöth J, Jerkeman M, Chang ET, Neovius M, et al. **Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time--a population-based comparative study.** Journal of cancer survivorship : research and practice. 2015;9(4):599-609.

Hårcellsleukemi

1. Juliusson G, Samuelsson H. **Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.** Leukemia & lymphoma. 2011;52 Suppl 2:46-9.

Mantelcellslymfom

1. Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D'Amore F, et al. **Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.** Blood. 2014;124(8):1288-95.
2. Abrahamsson A, Dahle N, Jerkeman M. **Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.** Leukemia & lymphoma. 2011;52(10):1929-35.

T-cellslymfom

1. Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, et al. **International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.** Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(36):4019-26.
2. Ellin F, Jerkeman M, Tornqvist J, Brudin L, Relander T. **Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study.** Hematological oncology. 2018;36(1):159-65.
3. Cederleuf H, Bjerregard Pedersen M, Jerkeman M, Relander T, d'Amore F, Ellin F. **The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.** British journal of haematology. 2017;178(5):739-46.
4. Cederleuf H, Hjort Jakobsen L, Ellin F, de Nully Brown P, Stauffer Larsen T, Bogsted M, et al. **Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.** Leukemia & lymphoma. 2017;58(12):2815-23.
5. Ellin F, Landstrom J, Jerkeman M, Relander T. **Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.** Blood. 2015;126(1):36-41.
6. Ellin F, Jerkeman M, Hagberg H, Relander T. **Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry.** Acta oncologica (Stockholm, Sweden). 2014;53(7):927-34.
7. Ellin F, Landstrom J, Jerkeman M, Relander T. **Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.** Blood. 2014;124(10):1570-7.

Myelodysplastiskt syndrom (MDS)

1. Moreno Berggren D, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ejerblad E. **Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.** Br J Haematol. 2018 Jun;181(5):614-627.
2. Moreno Berggren D, Kjellander M, Backlund E, Engvall M, Garelius H, Lorenz F, Nilsson L, Rasmussen B, Lehmann S, Hellström-Lindberg E, Jädersten M, Ungerstedt J, Ejerblad E. **Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.** Br J Haematol. 2021 Feb; 192(3):478-483.
3. Larfors G, Moreno Berggren D, Garelius H, Jädersten M, Nilsson L, Rasmussen B, Ejerblad E. **Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes.** Eur J Haematol. 2021 Aug;107(2):219-228.

Myeloproliferativa neoplasier (MPN)

1. Abdulkarim K, Samuelsson J, Johansson P, Andreasson B. **Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.** European journal of haematology. 2017;98(6):577-83.
2. Pettersson H, Knutsen H, Holmberg E, Andreasson B. **Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.** European journal of haematology. 2015;94(2):152-6.

Myelom

1. Nahi H, Genell A, Walinder G, Uttervall K, Juliusson G, Karin F, et al. **Incidence, characteristics,**

- and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.** European journal of haematology. 2017;99(3):216-22.
2. Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, et al. **Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR).** Haematologica. 2017.
 3. Kristinsson SY, Holmberg E, Blimark C. **Treatment for high-risk smoldering myeloma.** The New England journal of medicine. 2013;369(18):1762-3.